Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Mettler-Toledo International Inc.
MTD
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $26.3B
$1,296.89
▼ -0.27%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$1,023.05 - $1,525.17
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 7.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Global distribution network
- Advanced precision engineering
- Comprehensive technological ecosystem
- Strong research and development capabilities
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Expanding pharmaceutical and biotechnology markets
Value
Fairly valued vs Life Sciences Tools peers
Momentum
Stable
+3.2% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MTD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
MAY 7, 2026
Reported EPS of $8.91 vs $8.70 consensus (+2.4% surprise). Revenue of $947.1M vs $943.1M expected (+0.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+2.4%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+12%
-5%
+4%
+8%
+8%
+7%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$946.8M
$954.5M
$1.0B
$883.7M
$983.2M
$1.0B
$1.1B
$947.1M
Margins · last 8Q
Gross
—
Operating
—
Profit
17.9%
Wall Street consensus
8 analysts · 63% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
63%
Hold
38%
Sell
0%
Median Price Target
$1,400.00
▲ +8.0% vs $1,296.89
Latest: Stifel · $1,400.00 · May 18, 2026
3 analysts covering